What KUBOTA PHARMACEUTICAL HOLDINGS CO LTD's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Scheibler Lukas | EVP of Research & Development | Jul 17 | Sale for tax withholding · S | −1,250 | $6.50 | −$8.13K | 11,108 |
| Scheibler Lukas | EVP of Research & Development | Jul 17 | Exercise / conversion · M | +2,663 | — | — | 12,358 |
| Gebhart John E | Chief Financial Officer | Jul 05 | Sale for tax withholding · S | −3,700 | $6.75 | −$25K | 44,127 |
| Danse Edward H | Chief Business Officer | Jul 05 | Sale for tax withholding · S | −1,175 | $6.75 | −$7.93K | 68,959 |
| Gebhart John E | Chief Financial Officer | Jul 01 | Exercise / conversion · M | +7,473 | — | — | 47,827 |
| Scheibler Lukas | EVP of Research & Development | Jun 20 | Sale for tax withholding · S | −1,300 | $6.95 | −$9.04K | 9,695 |
| Scheibler Lukas | EVP of Research & Development | Jun 17 | Exercise / conversion · M | +2,664 | — | — | 10,995 |
| Gebhart John E | Chief Financial Officer | Jun 01 | Sale for tax withholding · S | −3,380 | $7.38 | −$24.9K | 40,354 |
| Gebhart John E | Chief Financial Officer | Jun 01 | Exercise / conversion · M | +7,473 | — | — | 43,734 |
| Danse Edward H | Chief Business Officer | Jun 01 | Sale for tax withholding · S | −1,080 | $7.38 | −$7.97K | 70,134 |
| Scheibler Lukas | EVP of Research & Development | May 17 | Sale for tax withholding · S | −1,275 | $6.15 | −$7.84K | 8,331 |
| Scheibler Lukas | EVP of Research & Development | May 17 | Exercise / conversion · M | +2,663 | — | — | 9,606 |
| Danse Edward H | Chief Business Officer | May 01 | Sale for tax withholding · S | −1,100 | $6.15 | −$6.77K | 71,214 |
| Gebhart John E | Chief Financial Officer | May 01 | Sale for tax withholding · S | −3,615 | $6.15 | −$22.2K | 36,261 |
| Gebhart John E | Chief Financial Officer | May 01 | Exercise / conversion · M | +7,473 | — | — | 39,876 |
| Scheibler Lukas | EVP of Research & Development | Apr 17 | Sale for tax withholding · S | −1,320 | $6.48 | −$8.55K | 6,943 |
| Scheibler Lukas | EVP of Research & Development | Apr 17 | Exercise / conversion · M | +2,664 | — | — | 8,263 |
| Gebhart John E | Chief Financial Officer | Apr 04 | Sale for tax withholding · S | −3,400 | $6.75 | −$23K | 32,403 |
| Danse Edward H | Chief Business Officer | Apr 04 | Sale for tax withholding · S | −1,100 | $6.75 | −$7.43K | 72,314 |
| Gebhart John E | Chief Financial Officer | Apr 01 | Exercise / conversion · M | +7,472 | — | — | 35,803 |
Loading...
